BioAge Labs, Inc.
BIOA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001709941
In the last 90 days, BioAge Labs, Inc. insiders filed 0 open-market purchases and 1 sale; 150 institutions reported holding it in 13F filings for Q2 2026, worth $924.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.58M in total
- 1
- 13F holdersQ2 2026, +9 vs. previous quarter
- 150
- 13F valueReported value at the end of Q2 2026
- $924.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding BIOA, Q2 2026
No superinvestor reported holding BIOA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by BioAge Labs, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)4:27 PM ET | Jun 29-30 | 2 days | Barton ShanePrincipal Accounting Officer | SSale | −62.6K | $25.20 | −$1.58M | −100.0%0 after | 2 lots10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Rubin Paul DChief Medical Officer | SSale | −8.82K | $17.81 | −$157.1K | −100.0%0 after | 10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Rubin Paul DChief Medical Officer | SSale | −7.43K | $20.30 | −$150.9K | −100.0%0 after | 10b5-1 |
| Feb 3, 2026 (view filing) | Feb 2 | 1 day | Rubin Paul DChief Medical Officer | SSale | −7.43K | $18.75 | −$139.4K | −100.0%0 after | 10b5-1 |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Fortney KristenChief Executive Officer | SSale | −233.1K | $18.12 | −$4.22M | −19.3%976.9K after | 10b5-1 |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Goldstein Dov A MDChief Financial Officer | SSale | −27.0K | $19.70 | −$531.8K | −54.6%22.4K after | 4 lots10b5-1 |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Rubin Paul DChief Medical Officer | SSale | −7.43K | $12.85 | −$95.5K | −100.0%0 after | 10b5-1 |
| Dec 11, 2025 (view filing) | Dec 9 | 2 days | Rubin Paul DChief Medical Officer | SSale | −18.0K | $12.00 | −$216.0K | −100.0%0 after | 10b5-1 |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Rubin Paul DChief Medical Officer | SSale | −68.9K | $10.19 | −$702.1K | −100.0%0 after | 10b5-1 |
| Mar 10, 2025 (view filing) | Sep 27, 2024 | 164 days | Hemrajani RekhaDirector | PPurchase | +3.00K | $18.00 | +$54.0K | New position3.00K after | Amended |
Top 10 13F holders, Q2 2026
The largest institutional positions in BioAge Labs, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AH Capital Management, L.L.C. | 3,233,170 | $79.2M | 0.56% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,849,077 | $69.8M | 0.00% | +581,321+25.6% | Added |
| Cormorant Asset Management, LP | 2,390,605 | $58.6M | 3.00% | −500,000−17.3% | Reduced |
| Sofinnova Investments, Inc. | 2,293,788 | $56.2M | 3.00% | 00.0% | Unchanged |
| Jupiter Topco LLC | 2,144,633 | $52.6M | 0.02% | +2,144,633 | New |
| Octagon Capital Advisors LP | 1,748,000 | $42.8M | 3.93% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 1,671,648 | $41.0M | 0.36% | +21,000+1.3% | Added |
| MPM Oncology Impact Management LP | 1,667,661 | $40.9M | 2.49% | +1,667,661 | New |
| Vanguard Capital Management LLC | 1,544,214 | $37.8M | 0.00% | +189,308+14.0% | Added |
| Polar Capital Holdings Plc | 1,072,344 | $26.3M | 0.07% | −60,296−5.3% | Reduced |